Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) saw a large growth in short interest in October. As of October 15th, there was short interest totaling 17,410 shares, a growth of 111.0% from the September 30th total of 8,251 shares. Based on an average trading volume of 6,891 shares, the short-interest ratio is currently 2.5 days.
Oculis Price Performance
Shares of NASDAQ:OCSAW remained flat at $2.45 during trading hours on Friday. Oculis has a 12 month low of $2.01 and a 12 month high of $22.64. The business has a fifty day moving average price of $3.30 and a 200-day moving average price of $9.75.
Oculis Company Profile
Oculis is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments. The company uses its proprietary OPTIREACH technology platform to develop eye-drop formulations designed to deliver medicines to tissues at the back of the eye, potentially addressing conditions that traditionally require injections or other invasive procedures.
Oculis’ development portfolio has included treatments for retinal diseases, glaucoma and ocular surface disorders. Its investigational products have targeted conditions such as diabetic macular edema, dry eye disease and neurodegenerative eye diseases.
Featured Articles
- Five stocks we like better than Oculis
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
- LyondellBasell’s Dividend Looks Safer, But a New Risk Could Change That
- L3Harris Stock Took a Beating—Is a 20% Rebound Next?
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
